IAVI 002

Status:Completed
Phase:I
Principal Investigator(s):
Objective:Evaluate the safety and immunogenicity of a candidate HIV-1 clade A DNA vaccine.
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Placebo, Randomized
Arms and Assigned Interventions
DescriptionOn Days 0 and 21 participants will receive a single injection of 500mg pTHr.HIVA in 1.0mL saline
Mode of DeliveryIntramuscular
ARMsExperimental
Official Code: IAVI 002
Trial Sponsors: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH)
Start Date
End Date
none
none
Enrollment:18
Age range: ↔ any
Population:Cisgender Men, Cisgender Women